AriñoHCoutinhoEPollakTA, et al. (2021) Real-world experience of assessing antibodies against the N-methyl-D-aspartate receptor (NMDAR-IgG) in psychiatric patients. A retrospective single-centre study. Brain, Behavior, and Immunity98: 330–336.
2.
CahalanS (2012) Brain on Fire: My Month of Madness. New York: Simon and Schuster.
3.
ChanFO’GormanCSwayneA, et al. (2021) Voltage-gated potassium channel blanket testing in first-episode psychosis: Diagnostic nihilism?Australian and New Zealand Journal of Psychiatry55: 817–823.
4.
DalmauJArmanguéTPlanagumàJ, et al. (2019) An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models. The Lancet Neurology18: 1045–1057.
5.
GalletlyCCastleDDarkF, et al. (2016) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry50: 410–472.
6.
JeppesenRNilssonACSørensenNV, et al. (2023) Antineuronal antibodies in cerebrospinal fluid and serum of 104 patients with psychotic disorders compared to 104 individually matched healthy controls. Schizophrenia Research252: 39–45.
7.
ScottJGGillisDRyanAE, et al. (2018) The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. BJPsych Open4: 69–74.
8.
WarrenNFlavellJO’GormanC, et al. (2020) Screening for anti-NMDAR encephalitis in psychiatry. Journal of Psychiatric Research125: 28–32.
9.
WarrenNFreierKSiskindD, et al. (2023) Anti-glutamic acid decarboxylase antibody screening in first-episode psychosis. Australian and New Zealand Journal of Psychiatry57: 603–612.
